✦ LIBER ✦

W1320 Natalizumab is Effective in the Treatment of Moderate to Severe Crohn's Disease Unresponsive to Anti-TNFα Agents

✍ Scribed by Elvanides, Harry S.; Burchett, Mary; Ingram, Karen R.; Annis, Kim; Arsenescu, Razvan I.; de Villiers, Willem J.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-Effectiveness of Third-Line Anti-TN

✍ Ananthakrishnan, Ashwin N. ;Hur, Chin ;Korzenik, Joshua R. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 63 KB

A new MAP-kinase inhibitor, CNI-1493, is

✍ Hommes, Daniel W.; van den Blink, Bernt; van de Heisteeg, Brenda; Plasse, Terry; 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 178 KB

Certolizumab pegol, a monthly subcutaneo

✍ Paul Rutgeerts; Stefan Schreiber; Brian Feagan; Dorothy L. Keininger; Liz O’Neil 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 250 KB

The lectin pathway of the complement sys

✍ Sandahl, Thomas Damgaard; Kelsen, Jens; Dige, Anders; Dahlerup, Jens Frederik; A 📂 Article 📅 2014 🏛 Oxford University Press 🌐 English ⚖ 474 KB

P.02.14 MAGNETIC RESONANCE ENTEROGRAPHY

✍ Annunziata, M.L.; Balestrieri, P.; Sansoni, I.; Coluccio, C.; Del Vescovo, R.; T 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 57 KB

A randomized, double-blind, placebo-cont

✍ Stephen Hanauer; Milan Lukáš; Donald MacIntosh; Paul Rutgeerts; William Sandborn 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 45 KB